Related Experiment Video
Updated: Nov 24, 2025

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Frontiers in HER2-positive breast cancer in 2020
Parvin F Peddi1, Dennis J Slamon
1University of California, Los Angeles, USA.
Purpose Of Review:
The field of HER2-positive breast cancer has seen tremendous advances in the last 2 years with largest number of new drugs in decades. The present review aims to summarize the cutting-edge research of the past 2 years and future directions.
Recent Findings:
This review will go over four new drugs, three of which have gained FDA approval within the past 18 months, in the treatment of HER2-positive breast cancer. We will go over early and mature clinical data on these therapeutics and ongoing clinical trials further exploring their role in the treatment of patients with advanced HER2-positive breast cancer and HER2 low breast cancer. Will also discuss ongoing trials using immunotherapy and CDK4/6 inhibitors in the advanced HER2-positive setting.
Summary:
: The therapies described in this review have quickly become standard of care for patients with HER2-positive breast cancer. Furthermore, they have the potential to change the landscape of breast cancer therapy further to include even patients with HER2 low breast cancer.
Insights
Recent advances in HER2-positive breast cancer treatment include four new FDA-approved drugs. These therapies are becoming standard of care and may extend to HER2-low breast cancer patients.
Area of Science:
- Oncology
- Medical Research
Background:
- HER2-positive breast cancer treatment has rapidly evolved.
- Significant advancements in therapeutic options have emerged in the last two years.
Purpose of the Study:
- To summarize cutting-edge research and future directions in HER2-positive breast cancer.
- To review recent drug approvals and clinical trial data.
Main Methods:
- Review of clinical data for four new drugs in HER2-positive breast cancer treatment.
- Analysis of ongoing clinical trials, including immunotherapy and CDK4/6 inhibitors.
- Examination of therapeutic roles in advanced and HER2-low breast cancer.
Main Results:
- Three new drugs have received FDA approval within the past 18 months.
- These novel therapies are rapidly establishing themselves as standard of care.
- Potential for expanded application to HER2-low breast cancer is indicated.
Conclusions:
- Recent therapeutic advancements represent a significant shift in HER2-positive breast cancer management.
- These new treatments offer improved options for patients with advanced disease.
- The scope of these therapies may broaden to include HER2-low breast cancer.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
10:01Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy